Overview

Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have advanced non-small cell lung cancer that cannot be treated with surgery.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Criteria
DISEASE CHARACTERISTICS: Histologically proven unresectable, locally advanced, progressive
or metastatic non-small cell lung cancer Not amenable to curative surgery or radiotherapy
No prior first line chemotherapy for metastatic or advanced disease At least 1
bidimensionally measurable target lesion by CT scan No symptomatic brain metastases

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
least 3 months Hematopoietic: WBC greater than 3,000/mm3 Platelet count greater than
100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) SGOT, SGPT,
and alkaline phosphatase no greater than 2 times ULN (5 times ULN if liver metastases
present) Renal: Creatinine no greater than 1.7 mg/dL Cardiovascular: No ischemic heart
disease within the past 6 months Normal 12 lead ECG Other: Not pregnant or nursing Negative
pregnancy test Fertile patients must use effective contraception No other prior or
concurrent malignancy except cone biopsied carcinoma of the cervix or adequately treated
basal or squamous cell skin cancer No unstable systemic disease or active uncontrolled
infection No psychological, familial, sociological, or geographical condition that could
preclude compliance

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At
least 4 weeks since prior radiotherapy Surgery: At least 2 weeks since prior major surgery
Other: No other concurrent anticancer agents No other concurrent investigational therapy